白血病細(xì)胞耐藥的產(chǎn)生是藥物治療中的一大阻礙，耐藥細(xì)胞過表達(dá)的跨膜轉(zhuǎn)運(yùn)蛋白（主要為P-糖蛋白）導(dǎo)致胞內(nèi)藥物濃度降低是產(chǎn)生耐藥的主要原因。此外，凋亡基因的異常表達(dá)、藥物作用靶點(diǎn)的改變也產(chǎn)生多藥耐藥（MDR）。針對(duì)這些特點(diǎn)尋找合適的藥品與化療藥合用以增加腫瘤細(xì)胞對(duì)化療藥的敏感性，或者利用高分子材料改變釋藥系統(tǒng)，以及開發(fā)新型藥物是逆轉(zhuǎn)白血病細(xì)胞耐藥的主要手段。通過對(duì)逆轉(zhuǎn)白血病MDR的方法進(jìn)行探討，旨在為白血病治療提供新思路。

The emergence of drug resistance in leukemia cells is a major obstacle for its treatment. The over-expression of transmembrane transporter proteins (mainly P-glycoprotein) in drug-resistant cells leads to a decrease in intracellular drug concentration which is the main reason for drug resistance. In addition, the abnormal expression of apoptotic genes and the change of targets also cause multidrug resistance (MDR). Suitable drugs combination with chemotherapeutics were found to increase the sensitivity of tumor cells to chemotherapeutic drugs, or the use of macromolecule materials to change the drug delivery system and develop new drugs are the main approaches to reverse the drug resistance of leukemia cells. Through the discussion of these ways of reversing leukemia MDR, it aims to provide new ideas for the treatment of leukemia.

國家自然科學(xué)基金資助項(xiàng)目（81473280）